/TLSI
TLSI Stock - TriSalus Life Sciences, Inc.
Healthcare|Medical - DevicesNASDAQ
$5.84-0.51%
$0.03 (-0.51%) • Jan 13
81
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.62
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+88.4%upside
Target: $11.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for TLSI
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$5.78 – $5.90
TARGET (TP)$11.00
STOP LOSS$5.37
RISK/REWARD1:11.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.43
52W High$7.95
52W Low$3.42
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $29.43M | $18.51M | $12.40M | $8.40M | N/A |
| Gross Profit | $25.33M | $15.91M | $10.14M | $7.21M | N/A |
| Gross Margin | 86.1% | 85.9% | 81.8% | 85.8% | N/A |
| Operating Income | $-36,165,000 | $-54,475,000 | $-36,439,000 | $-24,032,000 | $-108,493 |
| Net Income | $-33,233,000 | $-59,363,000 | $-47,187,000 | $-28,845,000 | $-31,830,000 |
| Net Margin | -112.9% | -320.7% | -380.6% | -343.4% | N/A |
| EPS | $-1.25 | $-2.23 | $-1.59 | $-0.92 | $-0.02 |
Company Overview
TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
5
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
5 Bullish0 Neutral/Bearish
Price Targets
$11
Average Target
↑ 90.1% Upside
Now
$10
Low
$11
Average
$13
High
Based on 5 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| February 13th 2025 | Lake Street | Initiation | Buy | - |
| December 17th 2024 | Cantor Fitzgerald | Initiation | Overweight | $10 |
| November 11th 2024 | ROTH MKM | Initiation | Buy | $11 |
| October 25th 2024 | Northland Capital | Initiation | Outperform | $12.5 |
| September 16th 2024 | Oppenheimer | Initiation | Outperform | $10 |
| May 30th 2024 | Canaccord Genuity | Initiation | Buy | $12 |
Earnings History & Surprises
TLSIBeat Rate
29%
Last 7 quarters
Avg Surprise
-69.9%
EPS vs Estimate
Beats / Misses
2/4
1 met exactly
Latest EPS
$-0.96
Q4 2025
EPS Surprise History
Q1 24
No data
Q2 24
+16.9%
$-0.54vs$-0.65
Q3 24
+57.1%
$-0.21vs$-0.49
Q4 24
-11.1%
$-0.40vs$-0.36
Q1 25
0.0%
$-0.35vs$-0.35
Q2 25
-65.0%
$-0.33vs$-0.20
Q3 25
-22.7%
$-0.27vs$-0.22
Q4 25
-464.7%
$-0.96vs$-0.17
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 26, 2026 | $-0.12 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.17 | $-0.96 | -464.7% | ✗ MISS |
Q3 2025 | Aug 12, 2025 | $-0.22 | $-0.27 | -22.7% | ✗ MISS |
Q2 2025 | May 15, 2025 | $-0.20 | $-0.33 | -65.0% | ✗ MISS |
Q1 2025 | Mar 27, 2025 | $-0.35 | $-0.35 | 0.0% | = MET |
Q4 2024 | Nov 14, 2024 | $-0.36 | $-0.40 | -11.1% | ✗ MISS |
Q3 2024 | Aug 14, 2024 | $-0.49 | $-0.21 | +57.1% | ✓ BEAT |
Q2 2024 | May 15, 2024 | $-0.65 | $-0.54 | +16.9% | ✓ BEAT |
Q1 2024 | Feb 27, 2024 | — | $-1.34 | — | — |
Q4 2023 | Nov 14, 2023 | — | $-0.13 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.53 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.31 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.76 | — | — |
Q4 2022 | Nov 10, 2022 | — | $-0.26 | — | — |
Q3 2022 | Aug 10, 2022 | — | $0.08 | — | — |
Q2 2022 | May 11, 2022 | — | $-0.25 | — | — |
Q1 2022 | Mar 2, 2022 | — | $0.09 | — | — |
Q4 2021 | Dec 13, 2021 | — | $0.06 | — | — |
Q4 2021 | Dec 13, 2021 | — | $-0.00 | — | — |
Q3 2021 | Aug 16, 2021 | — | $0.01 | — | — |
Latest News
TriSalus Posts $13.2M Q4 Revenue Vs $12.68M Est, $45.2M for 2025 Vs $44.62M Est, Guides $60M–$62M Sales in 2026 Vs $63.77M Est
➖ NeutralBenzinga•Jan 12, 2026, 12:23 PM
Canaccord Genuity Maintains Buy on TriSalus Life Sciences, Raises Price Target to $12
📈 PositiveBenzinga•Dec 17, 2025, 08:08 PM•Also:
TriSalus Life Sciences To Host Virtual KOL Event On Thyroid Disease And PED-TAE TriNav Infusion Approach On December 15, 2025 At 2:00pm ET
➖ NeutralBenzinga•Dec 4, 2025, 09:06 PM
TriSalus Life Sciences FY2025 Revenue expected to be more than $44.147M vs $45.216M Est
📉 NegativeBenzinga•Nov 13, 2025, 09:02 PM
TriSalus Life Sciences Q3 EPS $(0.96) Misses $(0.15) Estimate, Sales $11.566M Miss $11.760M Estimate
📉 NegativeBenzinga•Nov 13, 2025, 09:02 PM
TriSalus Life Sciences To Present Opinion On TriNav Infusion System, Review Uterine Artery Embolization On Nov. 12
➖ NeutralBenzinga•Nov 10, 2025, 01:07 PM
Frequently Asked Questions about TLSI
What is TLSI's current stock price?
TriSalus Life Sciences, Inc. (TLSI) is currently trading at $5.84 per share. The stock has moved -0.51% today.
What is the analyst price target for TLSI?
The average analyst price target for TLSI is $11.00, based on 1 analyst.
What sector is TriSalus Life Sciences, Inc. in?
TriSalus Life Sciences, Inc. operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the NASDAQ exchange.
What is TLSI's market cap?
TriSalus Life Sciences, Inc. has a market capitalization of $0.19 billion, making it a small-cap company.
Does TLSI pay dividends?
No, TriSalus Life Sciences, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARMP
Armata Pharmaceuticals, Inc.
$6.18
Mkt Cap: $0.2B
AVR
Anteris Technologies Global Corp.
$4.48
Mkt Cap: $0.1B
CATX
Perspective Therapeutics, Inc.
$2.62
Mkt Cap: $0.2B
LNSR
LENSAR, Inc.
$11.69
Mkt Cap: $0.1B
MXCT
MaxCyte, Inc.
$1.31
Mkt Cap: $0.1B
NNOX
Nano-X Imaging Ltd.
$2.96
Mkt Cap: $0.2B
OWLT
Owlet, Inc.
$14.10
Mkt Cap: $0.2B
PRE
Prenetics Global Limited
$15.91
Mkt Cap: $0.2B
PROF
Profound Medical Corp.
$8.75
Mkt Cap: $0.3B
STIM
Neuronetics, Inc.
$1.94
Mkt Cap: $0.1B
Explore stocks similar to TLSI for comparison